IP InterviewPublished May 15, 2022
Danaher, Beckman Coulter, & The DBS Machine
inpractise.com/articles/danaher-beckman-coulter-and-the-dbs-machine
Executive Bio
Executive Profile Hidden
Why is this interview interesting?
- How DHER changed Beckman and implemented DBS post-acq
- Why Beckman’s market share has declined from 90% to 30% in the last decade
- Why Danaher lost a core coagulation contract with IL
- Beckman’s challenge without an infectious disease product
Interview Transcript
Disclaimer: This interview is for informational purposes only and should not be relied upon as a basis for investment decisions. In Practise is an independent publisher and all opinions expressed by guests are solely their own opinions and do not reflect the opinion of In Practise.
Free Sample of 50+ Interviews
Sign up to test our content quality with a free sample of 50+ interviews.
Or contact sales for full access
Related Content
Profluent Bio: AI Protein Language Models for Gene Editor Design
Former Head of Business Development at Profluent Bio
Danaher: Cytiva / Pall Strategic Integration
Former Senior Director at Danaher
Cytiva vs Sartorius: A Vaccine Customer's Perspective
Vaccine Manufacturing Lead at Sanofi
Bruker and AI Applications in Mass Spectrometry
Former Director of Bruker
© 2024 In Practise. All rights reserved. This material is for informational purposes only and should not be considered as investment advice.